SynAct Pharma AB (GETTEX:8F8) Financings
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Convertibles of series 2026/2027:2 Closed: SEK 100M raised Buyers: Fenja Capital II A/S (second tranche of SEK 50 million) Use of proceeds: Strengthen financial position and support continued clinical development activities and strategic priorities | Nov 18, 2026 | |
| Private placement of new shares Closed: SEK 51.91M raised · SEK 18 a share · Navia Corporate Finance AB Dealers: Navia Corporate Finance AB (lead) Buyers: Hunter Capital (major shareholder that has expressed interest in participating); Johannes Schildt (major shareholder who has expressed interest in participating) Use of proceeds: Increased financial flexibility and extending the cash runway to support post-data partnering discussions | Mar 2, 2026 | US$5.67M |